Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Mass.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Mass.
Am J Med. 2021 Apr;134(4):e241-e251. doi: 10.1016/j.amjmed.2020.09.038. Epub 2020 Oct 27.
Administrative claims do not contain ejection fraction information for heart failure patients. We recently developed and validated a claims-based model to predict ejection fraction subtype.
Heart failure patients aged 65 years or above from US Medicare fee-for-service claims were identified using diagnoses recorded after a 6-month baseline period of continuous enrollment, which was used to identify predictors and to apply the claims-based model to distinguish heart failure with reduced or preserved ejection fraction (HFrEF or HFpEF). Patients were followed for the composite outcome of time to first worsening heart failure event (heart failure hospitalization or outpatient intravenous diuretic treatment) or all-cause mortality.
A total of 3,134,414 heart failure patients with an average age of 79 years were identified, of which 200,950 (6.4%) were classified as HFrEF. Among those classified as HFrEF, men comprised a larger proportion (68% vs 41%) and the average age was lower (76 vs 79 years) compared with HFpEF. History of myocardial infarction was more common in HFrEF (32% vs 13%), while hypertension was more common in HFpEF (71% vs 77%). One-year cumulative incidence of the composite endpoint was 42.6% for HFrEF and 36.9% for HFpEF. One-year all-cause mortality incidence was similar between the groups (27.4% for HFrEF and 26.4% for HFpEF), however, cardiovascular mortality was higher for HFrEF (15.6% vs 11.3%), whereas noncardiovascular mortality was higher for HFpEF (11.8% vs 15.1%).
We replicated well-documented differences in key patient characteristics and cause-specific outcomes between HFrEF and HFpEF in populations identified based on the application of a claims-based model.
行政索赔不包含心力衰竭患者的射血分数信息。我们最近开发并验证了一种基于索赔的模型,用于预测射血分数亚型。
从美国医疗保险按服务收费索赔中确定年龄在 65 岁或以上的心力衰竭患者,使用在连续登记的 6 个月基线期后记录的诊断来识别,该基线期用于识别预测因子并应用基于索赔的模型来区分射血分数降低或保留的心力衰竭(HFrEF 或 HFpEF)。对患者进行首次恶化心力衰竭事件(心力衰竭住院或门诊静脉利尿剂治疗)或全因死亡率的复合结局随访。
共确定了 3134414 例心力衰竭患者,平均年龄为 79 岁,其中 200950 例(6.4%)被归类为 HFrEF。在归类为 HFrEF 的患者中,男性比例较大(68%比 41%),平均年龄较低(76 岁比 79 岁)。HFrEF 中更常见心肌梗死史(32%比 13%),而 HFpEF 中更常见高血压(71%比 77%)。HFrEF 的复合终点一年累积发生率为 42.6%,HFpEF 为 36.9%。两组一年全因死亡率相似(HFrEF 为 27.4%,HFpEF 为 26.4%),但 HFrEF 的心血管死亡率较高(15.6%比 11.3%),而非心血管死亡率较高 HFpEF(11.8%比 15.1%)。
我们在基于索赔的模型应用确定的人群中复制了 HFrEF 和 HFpEF 之间关键患者特征和特定原因结局的记录在案的差异。